We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
LEDAGA (Recordati Rare Diseases Australia Pty Ltd)
Product name
LEDAGA
Date registered
Evaluation commenced
Decision date
Approval time
170 (255 working days)
Active ingredients
chlormethine hydrochloride
Registration type
NCE/NBE
Indication
LEDAGA (gel) is indicated for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-type CTCL) in adult patients.
Registration process
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.